Today (December 4, 2024), Duality Biologics announced that it has reached an exclusive licensing agreement with GlaxoSmithKline (GSK) for an antibody conjugated drug (ADC) DB-1324. According to the agreement, GSK will obtain the exclusive authorization of the world (excluding Chinese Mainland, Hong Kong and Macao) to promote the development and commercialization of the ADC drug.

According to the terms of the agreement, GSK will pay $30 million in advance and other pre exercise milestone payments to obtain an exclusive license to promote the R&D and commercialization of DB-1324 worldwide (excluding Chinese Mainland, Hong Kong and Macao). If GSK exercises its licensing rights, Yingen Biotechnology will charge an exercise fee and subsequent milestone payments at different stages of development, regulatory registration, and commercialization, up to a maximum of $975 million. After successful commercialization, GSK will pay different proportions of graded royalties to the global net sales (excluding Chinese Mainland, Hong Kong and Macao), and obtain royalties from the net sales in Chinese Mainland, Hong Kong and Macao.

DB-1324 is an innovative ADC molecule developed based on the Duality Immune Toxin Antibody Conjugates (DITAC) platform, which is unique and clinically validated by Innovent Biotech. At present, it is still in the preclinical development stage, and its research direction may focus on gastrointestinal (GI) cancers. In addition, the ADC drug has the potential to be used in combination with multiple anti-tumor products from GSK, strategically supplementing GSK's tumor product portfolio.

Dr. Hesham Abdullah, Senior Vice President and Global Head of Oncology Research at GSK, said, "GSK has been deeply involved in anti-tumor research for many years and hopes to create innovative ADC drug combinations. The ability of ADC lies in its ability to accurately target tumor cells while protecting normal cells. Based on this unique mechanism, GSK is confident in making ADC and its combinations a strategic priority for the company and developing innovative therapies for the most challenging tumors

Dr. Zhu Zhongyuan, founder and CEO of Yingen Biotechnology, said: "Yingen Biotechnology is committed to becoming a leading global next-generation ADC company. We are pleased to have reached a milestone cooperation agreement with GSK. Through this collaboration, we will jointly advance the pipeline of ADC drugs in the field of gastrointestinal cancer, meeting unmet clinical needs. DualityBio's unique ADC technology platform can continuously empower global partners and provide more innovative treatment options for cancer patients worldwide

Source: https://pharm.jgvogel.cn/c1467875.shtml